The hazard ratios for CDCA4 were significant for Pheochromocytoma and Paraganglioma (PCPG), ACC, KIRP, Cholangiocarcinoma (CHOL), KICH, KIRC, Acute Myeloid Leukemia (LAML), Brain Lower Grade Glioma (LGG), Bladder Urothelial Carcinoma (BLCA), LUAD, Mesothelioma (MESO), PAAD, PRAD, Skin Cutaneous Melanoma (SKCM), LIHC and uveal melanoma (UVM), among which CDCA4 had the highest risk effect in KICH (Figure 3A). Here, CDCA4 is linked to prostate adenocarcinoma.